

**CRYZ Blocking Peptide (C-term)**  
**Synthetic peptide**  
**Catalog # BP21584b****Specification****CRYZ Blocking Peptide (C-term) - Product Information**Primary Accession [Q08257](#)**CRYZ Blocking Peptide (C-term) - Additional Information****Gene ID** 1429**Other Names**

Quinone oxidoreductase, NADPH:quinone reductase, Zeta-crystallin, CRYZ

**Target/Specificity**

The synthetic peptide sequence is selected from aa 248-262 of HUMAN CRYZ

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**CRYZ Blocking Peptide (C-term) - Protein Information****Name** CRYZ**Function**

Does not have alcohol dehydrogenase activity. Binds NADP and acts through a one-electron transfer process. Orthoquinones, such as 1,2-naphthoquinone or 9,10-phenanthrenequinone, are the best substrates (in vitro). May act in the

**CRYZ Blocking Peptide (C-term) - Background**

Does not have alcohol dehydrogenase activity. Binds NADP and acts through a one-electron transfer process. Orthoquinones, such as 1,2-naphthoquinone or 9,10-phenanthrenequinone, are the best substrates (in vitro). May act in the detoxification of xenobiotics. Interacts with (AU)-rich elements (ARE) in the 3'-UTR of target mRNA species. Enhances the stability of mRNA coding for BCL2. NADPH binding interferes with mRNA binding.

**CRYZ Blocking Peptide (C-term) - References**

Gonzalez P., et al. Biochem. Biophys. Res. Commun. 191:902-907(1993).  
Gonzalez P., et al. Genomics 21:317-324(1994).  
Ota T., et al. Nat. Genet. 36:40-45(2004).  
Suzuki Y., et al. Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.  
Bechtel S., et al. BMC Genomics 8:399-399(2007).

detoxification of xenobiotics. Interacts with (AU)-rich elements (ARE) in the 3'-UTR of target mRNA species. Enhances the stability of mRNA coding for BCL2. NADPH binding interferes with mRNA binding.

**Cellular Location**

Cytoplasm.

**Tissue Location**

Only very low amounts in the lens.

**CRYZ Blocking Peptide (C-term) -  
Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)